Purpose: Carfilzomib is a next-generation, selective, proteasome inhibitor with clinical activity in relapsed and/or refractory multiple myeloma. The objectives of this phase I study were to establish the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of escalating doses of carfilzomib in patients with relapsed or refractory hematologic malignancies.
Introduction
The 20S proteasome is a central regulator of the cellular homeostasis through its function in ubiquitindependent turnover of proteins regulating signal transduction, cell-cycle progression, apoptosis, survival, and stress response pathways. Cancer cells seem to be particularly dependent upon these proteasome-regulated pathways (1) (2) (3) (4) . The 3 proteolytic activities of the 20S proteasome core include chymotrypsin-like, trypsinlike, and caspase-like activities (5) . The chymotrypsinlike activity is critical to cell survival and is a target of the clinically available proteasome inhibitors (6) . The proteasome was initially validated as a therapeutic target in multiple myeloma (7, 8) with the U.S. approval of bortezomib (Velcade, Millennium Pharmaceuticals).
Carfilzomib (formerly PR-171; Onyx Pharmaceuticals) is a next-generation proteasome inhibitor that is structurally and mechanistically distinct from boronate-based proteasome inhibitors such as bortezomib (9) (10) (11) . Although both target the proteasome's chymotrypsin-like activity, their mechanisms of action and selectivity differ due to their pharmacophores and peptide sequences (6) . Carfilzomib exhibits a high degree of specificity for the catalytic N-terminal threonine residues in each of the proteolytic active sites within the proteasome (9, 10) . The peptide portion of the carfilzomib confers a high degree of selectivity for chymotrypsin-like activity over the other 2 active sites of the proteasome (9) . In contrast, boronate proteasome inhibitors such as bortezomib, originally developed as potent serine protease inhibitors, retain some cross-reactivity against other proteases (11, 12) .
Another important distinction between carfilzomib and bortezomib is the stability of interaction of carfilzomib with the proteasome. Bortezomib is a slowly reversible inhibitor of the proteasome, and recovery from inhibition results from a combination of the off-rate from the enzyme and de novo synthesis of new proteasomes. In contrast, proteasome inhibition by carfilzomib is mechanistically irreversible (9, 10) as it involves the formation of 2 covalent bonds; new protein synthesis is therefore required for the recovery of cellular proteasome activity. Consequently, proteasome inhibition with carfilzomib is sustained over a longer period of time than with bortezomib (9) .
Mechanistic differences between carfilzomib and bortezomib may account for observed differences in preclinical antitumor and tolerability studies. In vitro, carfilzomib showed greater antitumor activity compared with bortezomib and overcame resistance to bortezomib and other conventional agents (13) . Moreover, studies showed that carfilzomib could potentially be administered clinically on consecutive days, thereby producing significant proteasome inhibition over extended periods of time, whereas bortezomib cannot (7) .
In human tumor xenograft studies, potent antitumor activity was seen when carfilzomib was administered on a weekly schedule of days (D) 1 and 2 (9) . Notably, the antitumor efficacy of carfilzomib delivered on 2 consecutive days was greater than that of bortezomib administered on its clinical dosing schedule (biweekly, D1/D4) in the same models. Readministration of carfilzomib before full recovery of proteasome activity resulted in optimal antitumor activity, supporting the hypothesis that prolonged proteasome inhibition (i.e., >48 hours) enhances antitumor activity in vivo.
Collectively, these findings led to the design of 2 separate phase I studies. In the first study (PX-171-001), carfilzomib was administered to patients with relapsed or refractory hematologic malignancies on a 2-week cycle, with doses up to 20 mg/m 2 given daily for 5 consecutive days, followed by 9 days of rest (14) . A dose of 15 mg/m 2 was established as the maximum tolerated dose (MTD) on this schedule and produced promising preliminary responses in patients with multiple myeloma and Waldenstr€ om's macroglobulinemia (14) .
In the present study (PX-171-002), carfilzomib was administered in a 4-week cycle (D1/2, D8/9, D15/16, followed by 12 days of rest). It was hypothesized that this regimen could display improved tolerability while still providing prolonged proteasome inhibition and disease control in patients with advanced hematologic malignancies. The safety, tolerability, and pharmacokinetic/pharmacodynamic profile from this study are presented herein.
Patients and Methods

Human patient protection and clinical trial registration
The protocol, informed consent, and other relevant study documentation were approved by the appropriate Institutional Review Boards before patient enrollment. All participants provided written informed consent in accordance with federal and local institutional guidelines. This trial was registered at www.clinicaltrials.gov as NCT00150462.
Eligibility criteria
Patients 18 years or more of age with histologically confirmed multiple myeloma, non-Hodgkin lymphoma (NHL), Waldenstr€ om's macroglobulinemia, or Hodgkin lymphoma (HL), and treatment-refractory or relapsed disease after 2 or more prior therapies were eligible for the study. Other key eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2, expected survival more than 6 weeks, no radiation, chemotherapy, or immunotherapy less than 4 weeks before study screening, and no active infections. Baseline white blood cell counts must have been 2 Â 10 9 /L or more, absolute neutrophil count (ANC) of 1 Â 10 9 /L or more, hemoglobin level of 8 g/dL or more, and platelet count of 50 Â 10 9 /L or more. Patients with prior bortezomib
Translational Relevance
The activity of the reversible proteasome inhibitor bortezomib in preclinical and clinical studies validated the proteasome as a therapeutic target in patients with a subset of hematologic malignancies including multiple myeloma. While subsequent incorporation of bortezomib into the treatment paradigm for multiple myeloma has had a favorable impact on the course of disease, resistance emerges in a significant proportion of patients, and painful peripheral neuropathy can severely limit treatment. Carfilzomib is a next-generation, irreversible proteasome inhibitor with increased selectivity for the proteasome's chymotrypsin-like active site. This second phase I study shows that carfilzomib is active and well tolerated on a dosing schedule of 2 consecutive days for 3 of 4 weeks in patients with relapsed and refractory hematologic malignancies, particularly multiple myeloma. These data support the further development of carfilzomib and provide the basis for the dosing schedule used in ongoing phase II and III clinical evaluation in multiple myeloma and other malignancies. treatment were eligible, as were patients with a history of peripheral neuropathy, provided the neuropathy was less than grade II at study entry. Other eligibility criteria included adequate cardiovascular, hepatic, and renal function (CrCL !30 mL/min).
Objectives
This study consisted of sequential dose-escalation and dose-expansion phases. The primary objectives of the study were to establish the safety, tolerability, and pharmacokinetic profile of escalating doses of carfilzomib in patients with relapsed or refractory hematologic malignancies. This included the determination of dose-limiting toxicity, identification of the MTD, and evaluating safety and tolerability at the recommended phase II dose with and without dexamethasone. Secondary objectives included determination of the pharmacodynamic profiles of escalating doses of carfilzomib and evaluation of preliminary evidence of antitumor activity.
Study design
Carfilzomib was provided as a sterile, frozen liquid formulation containing 2 mg/mL of carfilzomib (Onyx Pharmaceuticals, Inc). Patients were enrolled in cohorts of 3 to 6 individuals to receive carfilzomib in a dose-escalating fashion to establish the MTD. Planned dose levels ranged from 1.2 to 27 mg/m 2 . The initial carfilzomib dose level (1.2 mg/ m 2 ) was one-tenth of the severely toxic dose in 10% of animals based on the data from rodent studies (Onyx Pharmaceuticals, Inc; data on file). Carfilzomib was given as a 1-to 2-minute i.v. infusion on D1/2, D8/9, and D15/16 in each 28-day cycle. Dose escalation occurred according to a modified 3 þ 3 Fibonacci schema. For dose escalation, 3 assessable patients had to complete their first cycle without dose-limiting toxicities (DLT; Table 1 ). When 1 DLT was seen, an additional 3 assessable patients were accrued, and further escalation could occur if no additional DLTs were seen.
Patients continued to receive carfilzomib for up to 12 cycles or until disease progression or unacceptable toxicity per investigator assessment. Intrapatient dose escalation was permitted during the dose-escalation phase only after the intended dose was shown to be safe in the corresponding cohort.
The dose-expansion phase included a single-agent carfilzomib cohort and a carfilzomib þ dexamethasone cohort. Patients received carfilzomib at 20 mg/m 2 on day 1 and day 2 of cycle 1 and were dose-escalated to 27 mg/m 2 thereafter. On the basis of early observations in this study, preclinical data, and other carfilzomib trials including PX-171-001 and PX-171-003-A0, that carfilzomib administration may be associated with a first-dose infusion reaction variably characterized by a constellation of symptoms including fevers, chills, and/or dyspnea (14, 15) , some patients in the singleagent carfilzomib cohort received prophylactic dexamethasone (4 mg) in cycle 1 and at the first dose-escalation cycle to mitigate potential symptoms. Patients with multiple myeloma in the single-agent carfilzomib expansion cohort, who failed to achieve a partial response (PR) or better by cycle 2 or a complete response (CR) by cycle 4 could initiate treatment with dexamethasone 20 mg orally (120 mg/cycle) before each carfilzomib dose. Patients in the carfilzomib þ dexamethasone cohort received 20 mg oral dexamethasone before each dose of carfilzomib but did not receive the prophylactic 4-mg dose.
Safety criteria
Patients who received at least 1 dose of PR-171 were evaluated for safety. Safety and tolerability were evaluated by means of drug-related DLT, adverse events' reports, physical examinations, and laboratory safety evaluations.
Response criteria
All patients who received 1 cycle of treatment and who had both baseline and at least 1 posttreatment disease assessment were considered evaluable for response. Response was based on criteria defined by the European Group for Blood and Marrow Transplantation (EBMT) for patients with multiple myeloma (16), the International Working Group for patients with NHL and Hodgkin lymphoma (17) , and the Consensus Panel Recommendations from the Second International Workshop on Waldenstr€ om's macroglobulinemia for patients with Waldenstr€ om's macroglobulinemia (18) .
Pharmacokinetics
Blood samples for pharmacokinetic analysis were collected on C1D1, C1D2, C1D8, and C2D1 immediately before carfilzomib dosing and at 5, 15, 30, 60, 120, and 240 minutes after dosing. Plasma samples for pharmacokinetic studies were assayed using validated liquid chromatography/mass spectrometry, with a lower limit of detection of 0.10 mg/mL.
Pharmacodynamics
A pharmacodynamics assay measuring inhibition of proteasome chymotrypsin-like activity in whole blood and peripheral blood mononuclear cells (PBMC) was used (9) . Blood samples for pharmacodynamics assays were collected predose and 1-hour postdose on C1D1, C1D2, C1D8, and C2D1. Proteasome activity in all samples was compared with the C1D1 predose baseline value.
Data analysis
Adverse events were defined using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 (19) . Pharmacokinetics data were analyzed and modeled using WinNonLin Professional software, Version 5.2 (Pharsight Corp).
Results
Demographics
Forty-eight patients with relapsed or refractory hematologic malignancies were enrolled at 5 participating centers in the United States between September 2005 and April 2007. The dose-escalation phase enrolled 37 patients (21 multiple myeloma, 15 NHL, and 1 Hodgkin's lymphoma). The median age of enrolled patients was 61.4 years (range: 25-82 years) and the median time from diagnosis was 3.9 years (range: 0.7-13.7 years; Table 2 ). Eleven patients (7 multiple myeloma, 2 Waldenstr€ om's macroglobulinemia, and 2 NHL) were treated in the dose-expansion phase, including 7 in the single-agent carfilzomib cohort and 4 in the carfilzomib þ dexamethasone cohort. The median age for these patients was 65.0 years (range: 38-77 years) and the median time from diagnosis was 7.0 years (range: 3.1-22.9 years; Table 1 ).
Dosing
In the dose-escalation phase of the study, carfilzomib doses ranged from 1.2 to 27 mg/m 2 ( Table 3, ; the safety, pharmacokinetic, and biologic responses for these patients are reported according to their starting carfilzomib dose levels.
In the dose-expansion phase, all 11 patients initiated carfilzomib at a dose of 20 mg/m 2 ( Table 3 , dose expansion). Five of 7 patients in the single-agent carfilzomib cohort escalated to 27 mg/m 2 : 3 in cycle 1 and 2 in cycle 2. Two patients discontinued treatment in cycle 1. Of 4 patients in the carfilzomib þ dexamethasone cohort, 1 escalated to 27 mg/m 2 in cycle 1, 2 escalated to 27 mg/m 2 in cycle 2, and 1 discontinued treatment in cycle 1. Patients completed a mean of 3.9 to 4.0 cycles (range: 1-12).
Safety results
Adverse events were reported in all patients during the dose-escalation and the dose-expansion phases. Most adverse events were grade I/II in severity in both phases, with the exceptions of anemia and thrombocytopenia, a majority of which were grade 3 adverse events or more (Table 4; Supplementary Table S1 ). Two patients discontinued because of drug-related adverse events in the doseescalation portion of the study. No patients discontinued the study during dose expansion due to drug-related adverse events. Two patients had their doses reduced because of adverse events.
Hematologic adverse events
During the dose-escalation phase, the most common hematologic adverse events were anemia and thrombocytopenia (Table 5, Supplemental Table S1 ). A significant proportion of patients entered the study with abnormal hematologic parameters including grade I/II anemia (78%) and grade I/II thrombocytopenia (49%). During dose expansion, 4 of 11 patients experienced grade 3 or more hematologic adverse events possibly related to carfilzomib. Notably, all patients in the dose-expansion phase entered the study with grade I/II anemia, and 4 had grade I/II thrombocytopenia at baseline. Dosing of carfilzomib at 20 mg/m 2 was associated with a transient decrease in platelet counts that recovered during the 12-day rest period Table 3 . (Fig. 1A) . The effect was more pronounced at 27 mg/m 2 , with patients displaying a decrease in platelet counts from 25% to 50% with the first dose (Fig. 1B) . Increased occurrences of grade III anemia and grade IV thrombocytopenia were observed with carfilzomib doses of 20 mg/m 2 or more, although these were the only adverse events noted to increase in incidence or severity with dose level. The relative incidence of thrombocytopenia was greater in patients with multiple myeloma (43%) than in those with NHL/HD (19%). It is worth noting that 6 of the 12 patients who experienced adverse events of thrombocytopenia were in the 2 highest dosing groups, where the majority of patients (11 of 14) had multiple myeloma. Thrombocytopenia was not associated with any bleeding events at any dose in this study.
Nonhematologic adverse events
Nonhematologic adverse events were reported in more than 30% of patients during the dose-escalation phase (Table 4) . These events were primarily of grade I/II and were not life-threatening. No occurrences of grade III/IV treatment-emergent peripheral neuropathy were reported, despite 50% of patients having grade I peripheral neuropathy at the baseline.
The 27 mg/m 2 dose was associated with reversible grade I/II increases in creatinine in 3 of 6 patients, generally in association with blood urea nitrogen elevations. In addition, a reversible constellation of symptoms that included fever, chills, and rigors with a mild or moderate (grade I/II) increase in creatinine on day 2 before dosing was observed in 3 of 5 multiple myeloma patients receiving the 27 mg/m 2 dose. Elevation of creatinine was reversible and did not recur with carfilzomib rechallenge during subsequent cycles.
In the dose-expansion phase, nonhematologic adverse events were reported in more than 70% of patients. As in the dose-escalation phase, the majority of these events were of grade I/II and were neither severe nor life-threatening (Table 4) . Notably, there were no patients with peripheral neuropathy, and only 1 patient reported grade I paraesthesia. Hyperkalemia was observed in 3 patients in the doseexpansion cohort, and will continue to be evaluated in ongoing and future studies to determine its true incidence.
Serious adverse events
Three patients (8%) discontinued treatment during dose escalation with serious adverse events that were possibly or probably related to carfilzomib, including sepsis (n ¼ 1), elevated aspartate aminotransferase without significant alanine aminotransferase or other liver enzyme elevations (n ¼ 1), and chemical pancreatitis (n ¼ 1). Two deaths were reported during the study period or within 30 days of the last dose of carfilzomib: 1 patient with multiple myeloma died of progressive disease, and 1 patient with NHL died of septic shock and renal failure possibly related to both carfilzomib and underlying disease.
Five patients in the expansion cohort (45%) experienced a total of 9 severe adverse events. Of these events, only 1 (hypoxia) was assessed as related to study drug, although this resolved and did not recur with carfilzomib retreatment. Five patients (19%) continued treatment for more than 1 year without evidence of cumulative toxicity, and no specific target-organ toxicity was observed during long-term therapy.
Dose-limiting toxicities/maximum tolerated dose
There were 2 DLTs reported in 6 patients enrolled in the 27 mg/m 2 dose level during the study. However, in the final analysis, only 1 event (grade III hypoxia) was confirmed as meeting the DLT criteria. Among the 8 patients enrolled at the 20 mg/m 2 dose level, 1 case of acute renal failure (grade III) occurred in a patient who had grade II elevated creatinine at study enrollment. On the basis of a preliminary analysis of safety data from the highest dose groups and evidence of anti-myeloma activity at the 27 mg/m 2 dose, the study was subsequently amended to evaluate a conservative escalated dosing approach from 20 to 27 mg/m 2 on day 8 of the first dosing cycle in the dose-expansion cohorts. This regimen was well tolerated in 6 patients without an observation of a DLT. As a result, the 2 ongoing phase II trials (003 and 004) were amended to adopt this new maximum administered dose.
Pharmacokinetics
Because of a limited number of samples with detectable carfilzomib, insufficient sample volumes, and inaccurate or unconfirmed sample times, pharmacokinetics parameter estimates are reported only for the 11, 15, 20, and 27 mg/m 2 doses (Table 5 ). High inter-and intrapatient variability in the individual plasma concentrations and maximum plasma concentrations (C max ) of carfilzomib were observed, possibly reflecting differences in the rate of administration of carfilzomib and the timing of sample collections. Clearance was rapid, with a mean elimination half-life (t 1/2 ) generally less than 30 minutes. Because clearance was higher than liver blood flow, it can be postulated that significant hepatic clearance of carfilzomib is unlikely. The volume of distribution at steady state (V ss ) suggested wide tissue distribution of carfilzomib.
Pharmacodynamics
Carfilzomib induced a dose-dependent inhibition of the 20S chymotrypsin-like proteasome activity 1 hour Abbreviations: AUC last , area under curve to last measurable time point (includes C 0 ); CL, systemic clearance; C max , maximum plasma concentration; SD, standard deviation; t 1/2 , elimination half-life; V ss , volume of distribution at steady state.
after dosing on day 1. Doses of 15 mg/m 2 resulted in more than 80% proteasome inhibition in whole blood (Fig. 1C) and more than 70% inhibition in PBMCs (Fig.  1D) . At 27mg/m 2 , approximately 90% inhibition of proteasome activity was achieved in PBMCs. Minimal recovery of proteasome activity in whole blood between cycles was observed throughout the study, likely due to the inability of erythrocytes to synthesize new proteasome subunits (9) . In PBMCs, which are capable of subunit synthesis, minimal to no recovery in proteasome activity was seen in day 2 predose samples, suggesting that prolonged inhibition was achieved with carfilzomib administration ( Fig. 1E and F) . Proteasome inhibition after the second dose was equivalent to or greater than that seen with the first dose in both whole blood and PBMC samples. Substantial recovery of proteasome activity was observed in PBMCs before dosing in cycle 2 after a 12-day rest period (Fig. 1E and F) .
Response
Thirty-six patients were evaluable for response in the dose-escalation portion of the study, and 14 (39%) had objective responses or stabilization of disease (Table 6 ). Responses of minimal response (MR) or better were observed primarily in patients with multiple myeloma at doses of 15 mg/m 2 or higher, where proteasome inhibition is at least 70%. The patients remained in response between 5 and 14 cycles. No objective responses in patients with NHL/ HD were observed.
Nine patients were evaluable for response in the dose-expansion phase. Three of these patients had objective responses, including 2 PR (1 multiple myeloma, 1 Waldenstr€ om's macroglobulinemia), and 1 MR (multiple myeloma; Table 6 ). The 5 patients with multiple myeloma, who achieved responses of PR, continued to receive treatment for 6 months or more.
Discussion
On the basis of the in vitro and in vivo activity of carfilzomib observed in preclinical studies (9, 13, 20) , the current phase I study was designed to determine the safety and tolerability of carfilzomib in patients with relapsed and refractory hematologic malignancies using a 28-day dosing cycle. The overall safety profile of carfilzomib administered on this dosing schedule seems to be quite favorable, as carfilzomib doses up to the highest tested dose of 27 mg/m 2 were found to be tolerable and premedication with antiemetics and antidiarrheals was generally not required. The majority of adverse events across both phases of the study were grade I/II in severity and generally manageable. There were no episodes of grade III/IV peripheral neuropathy, despite 24 patients (50%) having entered the study with grade I peripheral neuropathy. These findings contrast with those seen with other proteasome inhibitors as well with many other classes of agents (e.g., alkylating agents and thalidomide) used to treat hematologic malignancies (21) .
There was a trend for the frequency and severity of the hematologic toxicities to be dose related. Cyclic thrombocytopenia was dose dependent and was observed primarily at the 27 mg/m 2 dose level and to a lesser extent at 20 mg/m 2 . This phenomenon has also been observed with bortezomib and is likely to be a proteasome inhibitor class effect on platelet budding from megakaryocytes (22) . However, it is important to note that the majority of the patients with multiple myeloma enrolled in the present study had low bone marrow reserve due to their rapidly progressing disease. The relative incidence of thrombocytopenia was greater in these patients than in those with NHL/HD, and a significant proportion of these events were attributable to disease progression. At the 27 mg/m 2 dose level, carfilzomib was also associated with a mild, transient, and reversible increase in creatinine, often accompanied by blood urea nitrogen elevations, consistent with a prerenal etiology. These findings are consistent with an infusion-like reaction. As a result, guidelines were instituted for use in the cycle 1 of ongoing carfilzomib studies to address the monitoring and management of infusion-like and renal-related events. These included extending the infusion time from approximately 2 minutes to 10 minutes, and the addition of low-dose dexamethasone (4 mg) before administration of carfilzomib. These prophylactic guidelines have contributed to the amelioration of the infusion-like reaction.
The pharmacokinetic properties of carfilzomib were similar to those reported in the 001 trial (14) . Clearance of carfilzomib occurred rapidly, and noncompartmental analysis revealed a mean elimination half-life of less than 30 minutes and no accumulation with repeat dosing. A more prolonged elimination half-life that seems to increase with repeat dosing has been reported for bortezomib, although similarly widespread tissue distribution has been observed (23) . The V ss also mirrored observations in the 001 trial, again suggesting a wide tissue distribution (9) . High interpatient and intrapatient variability in carfilzomib plasma concentrations were observed, likely due, in part, to variations in the duration of the i.v. infusion (2-10 minutes).
Because pharmacokinetic parameters were not likely to guide dosing, given the absence of dose-dependent increases in C max , AUC last , and t 1/2 , pharmacodynamics and safety parameters were evaluated more closely. The levels of proteasome inhibition observed with carfilzomib in contrast with those achieved using bortezomib on the D1/D4 schedule, where inhibitory activity plateaus at approximately 60% to 70% (24) . The tolerability of consecutive-day dosing and the irreversible mechanism of carfilzomib result in sustained inhibition of the chymotrypsin-like activity of the proteasome for more than 48 hours. Because bortezomib-resistant cells have been characterized by the overexpression of proteasome subunits (25) , longlasting, robust inhibition by carfilzomib (9) might overcome resistance induced by this mechanism. Further studies will be needed to elucidate the effect, if any, of bortezomibresistance on responses to carfilzomib, the impact of carfilzomib on the activity of the immunoproteasome, and the relationship of the extent of proteasome/immunoproteasome inhibition to the likelihood of response (i.e., a doseresponse relationship).
While not a primary focus of the study, efficacy results were encouraging. Objective responses or stable disease were observed in 14 of 36 patients with heavily pretreated hematologic malignancies, including 3 of 6 patients with multiple myeloma who had failed bortezomib as their last therapy. Responses generally occurred within the first or second cycle and persisted for more than 1 year with continued carfilzomib. However, the number of patients was too small, particularly in the dose-expansion portion of the study, to draw any meaningful conclusions. Further studies are needed to assess the effects of the carfilzomib dose and schedule, as well as the addition of dexamethasone (40 mg/week; 120 mg/28-day cycle).
In putting the current findings into perspective with the 001 study, a number of points should be considered. The 001 study used a more intensive dosing schedule of 5 consecutive days in a 14-day cycle and established a MTD at 15 mg/m 2 (14) . In the present study, a MTD was not established despite an adverse event profile that was largely similar to that seen in the 001 study; however, the consecutive-day dosing for 3 weeks of a 4-week cycle seems to have comparable, if not improved, tolerability at both 20 and 27 mg/m 2 . One notable difference was an apparent numerical increase in adverse events, particularly hematologic adverse events, with the current dosing schedule. While the number of patients per treatment group precludes a rigorous statistical analysis, there were fewer treatment discontinuations in this study. The efficacy data and pharmacokinetic profiles were similar between the 2 studies, although a direct comparison to the latter is technically challenging due to the high intrastudy variability and the pharmacokinetic properties of the drug.
Despite substantial inhibition of proteasome activity, long-term tolerability of carfilzomib was achieved without observed cumulative toxicities, and several patients remained on therapy for more than 1 year. Ongoing studies in larger patient populations support these observations (26, 27) . On the basis of these data, carfilzomib seems to offer a potentially non-cross-resistant mechanism of action with a favorable toxicity profile. The escalated dosing schedule, as used in the dose-expansion phase, was likely a contributing factor to the safety and tolerability seen in this study. The phase I observations presented herein, along with those from the earlier 001 study, provide a strong rationale for the dosing regimens and schedules for ongoing phase II studies in patients with multiple myeloma, as well as in patients with other hematologic malignancies or solid tumors. These studies include PX-171-003, which evaluated the efficacy of single-agent carfilzomib in patients with relapsed and refractory multiple myeloma, and PX-171-004, which evaluated the efficacy of single-agent carfilzomib in patients with relapsed multiple myeloma.
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